INBX - MCAP CO - Inhibrx Biosciences

Following the divestment of its primary asset to Sanofi, Inhibrx Biosciences (INBX) has focused on developing new antibodies, with the current metric standing at 1.46. Historical price action on the GURU.Markets platform reflects the valuations of a business that relies entirely on external contractors for manufacturing and testing. The absence of commercial products leaves the budget dependent on grants and third-party financing.

This metric is calculated as the product of the current share price and the total number of shares outstanding, providing a real-time assessment of the business's market valuation. The trend of this metric reveals the balance between fundamental stability and the risk of valuation overheating. For Inhibrx Biosciences (INBX), market capitalization accumulates confidence in their innovative protein engineering methods for cancer therapy. By analyzing the issuer's aggregate market capitalization, an investor sees the monetization of the company's scientific reputation. Peak values on this chart signal maximum market optimism.